MedTrace Logo

Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.

NCT06429345 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2024-06-28

No results posted yet for this study

Summary

In this study the investigators aim to study the effect of supplementation of CoQ10 in decreasing the incidence of contrast induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.

Conditions

  • Contrast-induced Nephropathy

Interventions

DRUG

Coenzyme Q10 100 Milligrams Oral Capsule

Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.

DRUG

Placebo

placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • RAMY Mohamed · Resident of cardiology department,Ain shams university

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-15
Primary Completion
2024-10-01
Completion
2024-11-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06429345 on ClinicalTrials.gov